Boston-based AI-powered peptide discovery company Perpetual Medicines has secured USD 8 million in a seed funding round led by Chengwei Capital.
The proceeds will be directed toward the development and enhancement of the company's integrated platform for peptide drug discovery and to accelerate its most advanced program to clinical stages.
Perpetual Medicines leverages its peptide drug discovery engine that integrates AI, computational physics, and synthetic chemistry to virtually iterate through millions of peptide sequences using physics-based computations to predict binding and drug-like properties. The company combines computational modeling, AI, and machine learning to discover and optimize drug candidates.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.